Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)-MedSci.cn

Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE (R)) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)

Ramalingam, SS; Ahn, MJ; Akamatsu, H; Blackhall, F; Borghaei, H; Hummel, HD; Johnson, M; Reck, M; Zhang, Y; Jandial, D; Cheng, S; Paz-Ares, L

ANNALS OF ONCOLOGY, 2022; 33 (): S103

科室
- - 订阅+
  - 更多科室
工具
服务